Nezam El-Tayebat Fact CheckA scientific assessment of the “نظام الطيبات” nutrition system
Choose country

Mostly true Certainty of evidence: moderate provisional C-CHM-02

After breast-cancer radiotherapy, the rate of major coronary events rises by 7.4% for every Gray of mean radiation dose to the heart, linearly and without threshold (Darby 2013).

Conclusion: The 7.4%/Gy figure is correct but relative; with modern doses the absolute risk is small and usually outweighed by the benefit.
  1. Original statement
  2. Scientific assessment
  3. In plain language
  4. Studies on this claim
  5. Regional context
  6. What applies in my country?
  7. References

Original statement

ارتفاع متناسب لأمراض القلب الإقفارية بـ7.4% لكل غراي من إشعاع الصدر

not verbatim – paraphrase. Translation by the project; the Arabic wording is authoritative.

Translation

After breast-cancer radiotherapy, the rate of major coronary events rises by 7.4% for every Gray of mean radiation dose to the heart, linearly and without threshold (Darby 2013).

Origin

Source status
Archive editors
Attribution
Archive editors (rule page summary/narrative)
Origin
https://eltayebat.com/rule/chemo-radiation/
Attribution uncertainty
Written by archive operators; not attributed to Elawady.
Claimed mechanism

Radiation damage to coronary arteries

Claimed health effect

Ischaemic heart disease

Population concerned

Women irradiated for breast cancer

Geographic restriction by Elawady

none found

Scientific assessment

Mostly true – Correct at its core, but with limitations or minor inaccuracies.

Certainty of evidence: moderate – Further research may still affect the assessment.

1. What was claimed?

7.4% per Gray increase in ischaemic heart disease after breast irradiation; 'the heaviest blow'.

2. What is demonstrably correct?

Darby et al. found +7.4% per Gy mean heart dose (95% CI 2.9-14.5), starting within 5 years and lasting into the third decade (A-CHM-04).

3. What is wrong or exaggerated?

The unit is mean dose to the heart, not 'per Gray of chest irradiation'. A relative 7.4%/Gy on a low baseline risk translates into small absolute risks with modern doses: estimated radiation-related cardiac mortality about 0.3% in non-smokers and about 1% in smokers (I-CHM-06). The same radiotherapy halves recurrence and reduces breast-cancer death (I-CHM-02).

4. What remains unclear?

Risk at very low modern heart doses with heart-sparing techniques.

5. Which studies support it?

A-CHM-04; I-CHM-06 (cardiac mortality RR 1.30; 0.04 excess RR per Gy).

6. Which studies contradict it?

I-CHM-02 (benefit); I-CHM-06 (absolute risk small for non-smokers).

7. What applies to Germany and Europe?

European centres use heart-sparing techniques; risk communication in absolute terms recommended.

8. What is known about Egypt?

Not studied; doses depend on equipment and techniques available.

9. What practical conclusion is appropriate?

Keep heart dose low and control cardiac risk factors (especially smoking); the benefit of indicated radiotherapy usually exceeds the cardiac risk.

Assessment details

Rationale for certainty of evidence

The figure is reported correctly from a well-conducted population-based case-control study; consistent with randomised-trial meta-analysis (I-CHM-06). Downgraded because the archive presents a relative per-Gy increase without absolute risk, and the Arabic summary refers to 'chest irradiation' instead of mean heart dose.

Source quality

Correctly cited landmark study.

Regional transferability

High.

Individual exceptions

Women with cardiac risk factors have larger absolute increases.

Regional scope of the claim
general (biological/medical)
Last reviewed
25 October 2026 provisional

In plain language

Radiation for breast cancer can reach the heart. Each extra unit of radiation dose to the heart increases the later risk of heart attack by a few percent. With modern techniques the heart dose is small, so the extra risk for a non-smoker is about 3 in 1,000. The same radiotherapy halves the chance that breast cancer comes back. Not smoking lowers the heart risk further.

Studies on this claim

Studies supporting the claim (1)

  • Radiation dose to the heart during breast-cancer radiotherapy raises later heart-attack risk

    Darby SC et al.. N Engl J Med 2013 · PMID 23484825 · DOI 10.1056/NEJMoa1209825
    Case-control studycited by the Tayebat archiveabstract only checked★ key study

    Each extra Gray of average heart dose increased the rate of major coronary events by about 7%.

    Source of the 7.4%/Gy figure

    Does the study support the specific claim? Yes · Methodological quality: high · Certainty of evidence: see overall assessment of the claim

    Original publication · Scientific details

    Study explained simply
    What did the researchers want to find out?

    Measure heart risk by radiation dose.

    How was the study done?

    Case-control with dose reconstruction.

    How many people, animals or samples were studied?

    2,168 women.

    What was actually found?

    +7.4% per Gy, linear.

    How large was the observed effect?

    ERR 7.4%/Gy (2.9-14.5).

    What do the results mean in everyday life?

    Keep heart dose as low as possible; control cardiac risk factors.

    What are the study's limitations?

    Historical doses; relative measure.

    What does it say about Elawady's specific claim?

    Confirms the archive number.

    Do the results apply to Germany and Europe?

    High.

    What can explicitly not be concluded from this study?

    That radiotherapy does net harm.

    Scientific details →

Studies contradicting or limiting the claim (2)

  • With modern techniques, radiotherapy's heart and lung risks are small for non-smokers

    Taylor C et al.. J Clin Oncol 2017 · PMID 28319436 · DOI 10.1200/JCO.2016.72.0722
    Meta-analysisindependent cross-checkabstract only checked★ key study

    About 0.3% risk of radiation-related heart death or lung cancer in non-smokers, higher in smokers.

    Absolute risk small with modern doses

    Does the study support the specific claim? Partly · Methodological quality: high · Certainty of evidence: see overall assessment of the claim

    Original publication · Scientific details

    Study explained simply
    What did the researchers want to find out?

    Estimate absolute RT risks.

    How was the study done?

    Dose review + IPD meta-analysis.

    How many people, animals or samples were studied?

    40,781 women.

    What was actually found?

    Small absolute risks; smoking key.

    How large was the observed effect?

    Cardiac mortality RR 1.30.

    What do the results mean in everyday life?

    Stop smoking before/after radiotherapy.

    What are the study's limitations?

    Smoking modelled.

    What does it say about Elawady's specific claim?

    Puts Darby in perspective.

    Do the results apply to Germany and Europe?

    High.

    What can explicitly not be concluded from this study?

    Individual dose-specific risk.

    Scientific details →

  • Radiotherapy after breast-conserving surgery halves recurrence

    EBCTCG. Lancet 2011 · PMID 22019144 · DOI 10.1016/S0140-6736(11)61629-2
    Meta-analysisindependent cross-checkfull text checked★ key study

    Recurrence within 10 years fell from 35% to 19%, and breast-cancer deaths within 15 years from 25% to 21%.

    Benefit context for the heart risk

    Does the study support the specific claim? No · Methodological quality: high · Certainty of evidence: see overall assessment of the claim

    Original publication · Scientific details

    Study explained simply
    What did the researchers want to find out?

    Measure radiotherapy benefit.

    How was the study done?

    IPD meta-analysis.

    How many people, animals or samples were studied?

    10,801 women.

    What was actually found?

    Recurrence halved; breast-cancer deaths about one-sixth lower; deaths from any cause at 15 years 3.0 percentage points lower.

    How large was the observed effect?

    -15.7% recurrence; -3.8% death.

    What do the results mean in everyday life?

    Radiotherapy markedly lowers the chance the cancer returns.

    What are the study's limitations?

    Older techniques; risk groups derived from the same data; in low-risk node-negative women the gain in survival was small and uncertain.

    What does it say about Elawady's specific claim?

    Benefit side.

    Do the results apply to Germany and Europe?

    High.

    What can explicitly not be concluded from this study?

    Individual benefit size without risk factors.

    Scientific details →

Studies with mixed or unclear results (0)

No studies in this group.

Regional context

Germany / EU

European centres use heart-sparing techniques; risk communication in absolute terms recommended.

Egypt

Not studied; doses depend on equipment and techniques available.

What applies in my country?

General scientific assessment

Mostly true The 7.4%/Gy figure is correct but relative; with modern doses the absolute risk is small and usually outweighed by the benefit.

This statement concerns biological or medical relationships. The scientific assessment above applies regardless of the country; country-specific food data do not change it.

References

  1. Risk of ischemic heart disease in women after radiotherapy for breast cancer.. Darby SC et al.. N Engl J Med 2013 · PMID 23484825 · DOI 10.1056/NEJMoa1209825
  2. Estimating the Risks of Breast Cancer Radiotherapy: Evidence From Modern Radiation Doses to the Lungs and Heart and From Previous Randomized Trials.. Taylor C et al.. J Clin Oncol 2017 · PMID 28319436 · DOI 10.1200/JCO.2016.72.0722
  3. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials.. EBCTCG. Lancet 2011 · PMID 22019144 · DOI 10.1016/S0140-6736(11)61629-2

← Back to overview